Also found in: Wikipedia.
LTRALeukotriene Receptor Antagonist
LTRALong-Term Response Action
LTRALong Term Remedial Action
LTRALong-Term Repopulating Ability (stem cells)
LTRALow Temperature Requirement A (protein)
LTRALong-Term Rental Assistance Program (City of Miami Community Development; Miami, FL)
References in periodicals archive ?
Combination therapy typically involves antihistamines to block the histamine released from mast cells and basophils, LTRAs (leukotriene receptor antagonists) to block leukotrienes, and nasal corticosteroids to block the various inflammatory mediators that participate in allergic reactions.
In the first study 306 patients were randomly assigned to open-label treatment with either an LTRA (montelukast or zafirlukast) or an inhaled glucocorticoid (beclomethasone, budesonide, or fluticasone) as first-line therapy.
LTRAs, sold under the brand names "Singulair" (montelukast) and "Accolate" (zafirlukast), have long been on the market as an alternative to the steroid inhalers commonly used by asthmatics to ward off attacks.
For children older than 5 years: Options for stepping up treatment include increasing the dose of ICS (medium dose) or adding a LABA or LTRA.
They found that tablets called leukotriene receptor antagonists (LTRAs) managed the disease equally successfully as steroid inhalers for patients with mild asthma and in a parallel sample of patients with moderate asthma, LTRAs managed the disease equally successfully as other "preventer" inhalers when used in addition to steroid inhalers.
1] improvements independent of concomitant LTRA use[interaction P = 0.
ULTRAV LTRAV LTRA OX star Midge Ure has spoken of how hard it was to write a letter of sympathy to his old pal Bob Geldof after his 25-year-old daughter Peaches died.
LTRAs, sold under the brand names Singulair and Accolate, have long been available as alternative treatments to ward off asthma attacks.
Montelukast and zafirlukast are LTRAs that block the actions of leukotrienes, thereby preventing airway hypersensitivityincreased mucus secretion, and increased vascular permeability by alleviating airway inflammation.
Responders do not develop tolerance and in view of their beneficial effect on rhinitis symptoms, LTRAs are particularly indicated in those patients who have both asthma and rhinitis.
As add-on therapy to corticosteroids in the treatment of moderate asthmatics, improvements of asthma control have been achieved with the LTRAs which are comparable with those of LABAs, (8) although a recent Cochrane meta-analysis suggested that LABAs were superior to LTRAs in preventing exacerbations, and for improving lung function, symptoms, and use of rescue therapy.
Studies are currently investigating the role of LTRAs as an option in such cases.